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We aimed to investigate the effects of methylphenidate (MPH) in healthy rats on two
distinct radial maze tasks which rely on brain structures and neurotransmitters known
to be affected by MPH: the Random Foraging Non-Delay Task (RFNDT) and the Delayed
Spatial Win Shift Task (DSWT). Hooded Lister rats were trained to complete either the
RFNDT or the DSWT having received oral treatment of either a vehicle or MPH (3.0mg/kg
and 5.0mg/kg for RFNDT, 3.0mg/kg for DSWT). We found no effect of MPH on the
RFNDT relative to the control group. However, those treated with 5.0mg/kg MPH did take
significantly longer to reach criterion performance than those treated with the 3.0mg/kg
MPH, suggesting some doses of MPH can have detrimental effects. For the DSWT, if MPH
was present in both phases, performance did not differ from when it was absent in both
phases. However, when present in only one phase there was an increase in errors made,
although this only reached significance for when MPH was present only in the test-phase.
These data suggest that MPH may have detrimental effects on task performance and can
result in state-dependent effects in healthy individuals.
Keywords: cognitive enhancement, radial maze, state-dependent effects, hippocampus, prefrontal cortex, nucleus
accumbens, dopamine
INTRODUCTION
The term “nootropic” was coined in 1964 to mean drugs capa-
ble of enhancing cognition. At the time it referred to a limited
range of drugs that improved performance on simple learning
and memory tasks in rodents. Almost 50 years later, “nootropic”
has been replaced by “cognitive enhancer” and the focus is
on drugs such as methylphenidate (MPH) and their effects in
humans. MPH is commonly used to treat Attention Deficit
Hyperactivity Disorder (ADHD) but there is increasing off-label
use by healthy individuals seeking to boost cognition (Morris,
2008). It is reported that, on average, 7% of US university stu-
dents are using cognitive enhancers, a figure that rises to 25%
at some institutions (Sahakian and Morein-Zamir, 2007; Greely
et al., 2008).
Despite this increasing use of MPH in healthy individuals,
research into its effects has largely been conducted in those diag-
nosed with ADHD. Although the neurobiology of ADHD is not
fully understood, it is generally accepted that the pathophysiology
includes a role for both dopamine and noradrenalin (Arnsten,
2009; Del Campo et al., 2011). Both of these are affected by
MPH. It would therefore be remiss to assume that the effects on
cognition observed in this clinical population, with abnormali-
ties in the very systems where the drug acts, would be mirrored
in a healthy population. Of the limited research that has been
conducted with a non-clinical population, improvements have
been found in self-reported measures of attention (Koelega, 1993;
Advokat et al., 2010), attention set shifting (Rogers et al., 1999),
recall (Camp-Bruno and Herting, 1994), digit span (Agay et al.,
2010), and spatial working memory (Elliott et al., 1997; Mehta
et al., 2000). However, the exact effects of MPH depend on a
number of factors. For example, it may be detrimental where per-
formance is already established (Elliott et al., 1997) and where
enhancement does occur it appears to be baseline dependent such
that improvements are only found in those who perform poorly
at baseline (Clatworthy et al., 2009).
Whilst research in non-clinical human populations has been
limited, research in healthy animals has been more plentiful. This
is largely due to the lack of an ideal animal model of ADHD
which has resulted in the tendency to use healthy rat strains in
MPH studies. However, findings in rats are inconsistent. Positive
effects have been reported on a radial maze spatial memory
task (Zhu et al., 2007), retention of contextual fear respond-
ing (Bethancourt et al., 2009), and long term potentiation and
depression mechanisms (Dommett et al., 2008), but no effects
have been reported on complex stimulus discrimination tasks
(Galizio et al., 2009), or water maze performance (McFadyen
et al., 2002). Furthermore, impairment of object recognition has
also been observed (Chuhan and Taukulis, 2006).
In addition to the relative dearth of studies into the effects of
MPH in healthy individuals, the majority of studies with humans
have used acute drug administration (Camp-Bruno and Herting,
1994; Elliott et al., 1997; Rogers et al., 1999; Mehta et al., 2000;
Agay et al., 2010), which may not reflect the pattern of use in
healthy humans where the drug could be taken over a longer
time, for example during revision and exam periods. Indeed,
a recent review and meta-analysis of the effects of MPH and
modafinil in healthy humans, encompassing all single, or dou-
ble blind placebo controlled studies, revealed only two studies
with repeated administration (Repantis et al., 2010). The first of
these found no effects on anymeasures collected (memory, mood,
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or wakefulness) (Gilbert et al., 1973), whilst the second found
only an increase in anxiety following MPH treatment (Gobbi
et al., 2003). The use of repeated drug administration is more
common in animal work with the majority of the studies out-
lined above using repeated administration (McFadyen et al., 2002;
Zhu et al., 2007; Bethancourt et al., 2009; Galizio et al., 2009).
Nevertheless, many of the studies using repeated administration
in animals have administered the drug by injection which does
not give comparable pharmacokinetics to the oral administration
used in humans. In addition,many used doses that do not provide
comparable blood plasma levels to those found in humans tak-
ing the drug (Kuczenski and Segal, 2002). Therefore, even where
repeated administration has been used, relevance to human use is
limited.
Examination of the neurochemical effects of orally admin-
istered MPH may provide useful insights into what kind of
behavioral measures might be sensitive toMPH-induced changes.
As stated above, MPH affects both dopamine and noradrenalin by
acting as a reuptake blocker for both monoamines. Given the dif-
fuse innervation of these monoamines fibers, the effects on the
brain are likely to be widespread. However, three structures have
been the focus of a number of studies using oral administration
in the rat at doses relevant to humans: the nucleus accumbens
(NAc), prefrontal cortex (PFC), and hippocampus. These stud-
ies have revealed that acute orally administered MPH increased
dopamine in the NAc (Kuczenski and Segal, 2002; Berridge et al.,
2006) and in the PFC (Berridge et al., 2006) and increased nora-
drenalin levels in the hippocampus (Kuczenski and Segal, 2002).
In all cases increased neurotransmitter was found after 20min
and persisted for at least a further 20min (Kuczenski and Segal,
2002; Berridge et al., 2006). Given this information, it seems prob-
able that cognitive tasks reliant on these brain regions that can
also be conducted within the 20min time period during which
MPH has increased neurotransmission, are likely to be sensitive
to MPH.
The PFC-NAc-hippocampal circuitry has been implicated in
two distinct types of spatial memory, which can be differentiated
using a radial maze. Originally developed to test hippocampal-
dependent memory (Olton and Papas, 1979), it is now clear there
is a role for the prelimbic area of the PFC as well as the NAc
(Seamans and Phillips, 1994; Seamans et al., 1995; Floresco et al.,
1997) in radial maze performance. These two regions are strongly
connected with the ventral CA1/subciculum region of the hip-
pocampus (Groenewegen et al., 1987; Jay andWitter, 1991) and at
a behavioral level this connectivity supports two distinct strategies
for spatial foraging. The prelimbic PFC to hippocampus connec-
tion plays a role specifically in a delayed spatial win shift task on
the radial maze (DSWT). This task has two phases separated by a
delay. Successful foraging for 4/8 baited arms in the second phase
is reliant on accurate memory of food location prior to the delay,
as well as a shift strategy because food is located in the four arms
that were not baited in the first phase (the exact location of baited
arms changes every day). The PFC dependency occurs because
rats begin the second phase with prior information about where
to locate food reward and must recall this, actively updating their
memory as they work through to complete this second phase. In
contrast to the PFC, the NAc appears to be involved in successful
performance of both the DSWT and a random foraging non-
delay task (RFNDT), indicative of a general role in goal-directed
motor behavior (Kelley and Stinus, 1985; Mogenson et al., 1993;
Yin et al., 2008).
Therefore, given the known pharmacological effects of orally
administered MPH on the three key regions involved in radial
maze performance and knowledge of the specific radial maze task
demands that depend on these structures, and the connections
between them, we suggest these are the optimal task in which to
investigate cognitive enhancing effects of MPH. As such we inves-
tigated the effects of orally administered MPH in healthy Hooded
Lister rats by examining acquisition of the RFNDT and DSWT,
hypothesizing that orally administered MPH would improve per-
formance on both tasks in comparison to rats treated with a
vehicle solution.
MATERIALS AND METHODS
SUBJECTS
A total of fifty-four male Hooded Lister rats (Harlan, UK) aged
60 days at the start of testing were used. Rats were housed at a
constant temperature of 21–23◦C on a 12:12 h light/dark cycle
in cages of three and placed on food restriction such that they
received a daily amount of 18 g of lab chow per rat. This level
ensured healthy growth but sufficient motivation to complete the
tasks. Rats were weighed daily throughout the study. Behavioral
testing took place during the light period and feeding occurred
once all rats had been tested each day. All work was conducted
in line with local ethical procedures and the Animals (Scientific
Procedures) Act 1986.
APPARATUS
Behavioral training and testing was carried out on an elevated
eight arm, gray plastic radial maze. There was a food cup posi-
tioned 1 cm from the far end of each arm and guillotine style
doors were used to restrict access to the arms when necessary. The
central platform was 45 cm in diameter and the arms were 68 cm
long and 10 cmwide. The arms of the maze did not have full sides.
Rather they had a 2 cm lip on all sides of arms which allowed
maximum visibility of the animal and reward pellet by the exper-
imenter. Where the arms connected to the central platform the
height of the side increased to that of the guillotine doors (12 cm)
over a length of 10 cm. This was necessary to prevent rats mov-
ing directly from one arm to another without travelling via the
central platform. The maze was elevated 50 cm above the floor.
Observations were directly recorded onto the PC using a specially
written Python programme. There were some extra maze cues
in the testing room (signs of black and white symbols and other
equipment) but these remained constant throughout the study.
RANDOM FORAGING NON-DELAY TASK (RFNDT)
A total of thirty-six rats were used for this task. They were
split into two cohorts for testing because of the time-consuming
nature of the task. The first cohort received either treatment with
3.0mg/kg MPH (N = 9) or vehicle (N = 9), whilst the second
cohort received either treatment with 5.0mg/kg MPH (N = 9)
or vehicle (N = 9). This approach was taken to avoid using a
historical control group.
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The RFNDT has been described before (Keating and Winn,
2002) and is illustrated in Figure 1A. Prior to training on this
task all rats were habituated to the experimenter and the maze.
In addition, they were habituated to the reward pellets in the
home cage. A single trial of the RFNDT required the rat to find
four reward pellets from eight open arms. Pellets were raspberry-
flavored 45mg pellets (TestDiet 5TUM 18123372, Sandown
Scientific, UK). Although these pellets were not odorless previous
work has confirmed that this task does not rely on olfactory cues
(Olton and Samuelson, 1976; Zoladek and Roberts, 1978; Olton
and Collison, 1979). The pellets were placed in four randomly
chosen arms on each trial using a random number table such that
FIGURE 1 | (A) The RFNDT required the rat to locate four pellets located in
randomly chosen arms with all eight arms open. (B) The DSWT task had
two phases: the training phase in which four randomly selected arms were
open and baited, and the test phase, in which all arms were open and the
four previously closed arms were baited.
no more than two consecutive arms were baited or unbaited in a
trial, and at least one arm was different from the previous day’s
trial. At the start of each trial the rat was placed on the central
platform and given 10min to find all four pellets. When all pellets
had been eaten (or 10min elapsed) the rat was removed from the
maze and returned to its home cage. The maze was washed down
with alcohol spray between each trial to remove olfactory cues
from each rat. Arm entries were recorded once the animal had all
four paws on the arm. Arm exits were recorded once the animal
had all four paws on the central platform. Each rat underwent
one trial per day. The dependent variables were recorded direct to
a Python computer programme by an observer in the room who
was blind to the drug condition. The dependent variables were:
latency to first arm choice; mean arm choice time (defined as the
total time on the maze divided by the number of choices made);
number of unbaited entries; number of unbaited re-entries; num-
ber of baited entries; number of baited re-entries; and total
number of re-entries. This last variable, “total number of re-
entries,” was used for determining criterion performance which
was defined as a rat collecting all four reward pellets with one or
less re-entry error over 2 consecutive days. On an individual basis
this was applied to determine “expertise” on the task. Testing was
continued for all rats until the final animal had reached criterion.
The number of pellets eaten was also recorded throughout but
very early on in testing this consistently reached the maximum
and therefore came to equal the number of baited arm entries.
All data were deemed suitable for analysis with parametric tests
following normality checks using the Kolmogorov-Smirnov test
and, where necessary, corrections for violations of homogene-
ity of variance were applied (Greenhouse-Geisser). Additionally,
analysis revealed that the control groups from each cohort did not
differ significantly from each other on anymeasures and therefore
the data from the two cohorts were combined into a single, more
powerful analysis (N = 9 for each drug dose andN = 18 for vehi-
cle). The number of trials needed to reach criterion were analyzed
using a One Way ANOVA. All other variables were analyzed with
a 1 within (TRIAL), 1 between (TREATMENT) ANOVA.
Following completion on the RFNDT all animals underwent a
single 75min session of locomotor monitoring using automated
Activity Monitoring Chambers (Med-Associates). By this point
animals tested in the first batch (control and low dose) were
165 days old and those in the second (control and high dose)
were 126 days old. This allowed at least 1 month between the
final test day on the maze and locomotor testing. This was nec-
essary in order to determine whether drug treatment significantly
altered locomotor activity in a way that could explain or confound
RFNDT performance. Animals were habituated to the chambers
for 15min on 2 consecutive days before monitoring took place.
For data collection, rats received treatment as per the condi-
tions of the RFNDT (i.e., the same treatment was provided such
that overall there were N = 9 3.0mg/kg, N = 9 5.0mg/kg, and
N = 18 Vehicle). Data were binned into 5min blocks and col-
lected for the full 75min. This duration was selected as it has
previously been shown to be sufficient for neurotransmitter levels
to return to pre-MPH levels (Kuczenski and Segal, 2002). Four
behavioral measures were recorded: ambulatory counts (num-
ber of beam breaks), ambulatory distance (horizontal distance
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travelled), average velocity, and stereotypic activity (any partial-
body movements that occur within a defined space, such as
head-weaving, or scratching movements but may also include
grooming). As with the RFNDT data, Kolmogorov-Smirnov tests
were used to confirm normality of distribution, and the two
cohorts were collapsed after tests revealed no significant differ-
ences between the two control groups on any measure, allow-
ing combined analyses. Data were analyzed using a 1 within
(BLOCK), 1 between (TREATMENT) ANOVA.
DELAYED SPATIAL WIN SHIFT TASK (DSWT)
The remaining 18 rats were used for the DSWT. This task has
also been described in detail before (Keating and Winn, 2002;
Taylor et al., 2003, 2004) and is illustrated in Figure 1B. As with
the RFNDT each rat underwent one trial per day. A single trial
of the DSWT consists of two phases. The first phase (training
phase) requires the animal to find four food rewards from four
open arms, with the remaining four arms blocked off. Baited arms
are randomly chosen each day and no more than two consecu-
tive arms are allowed. In the second post-delay phase (test phase),
the animal is required to find four reward pellets from eight open
arms. In this phase the pellets are placed in the arms that did not
contain pellets in the training phase. The animal must therefore
“shift” to “win” the task and find the four pellets in the test phase.
All animals were trained to a criterion of completing both the
training and test phases with no more than five total arm entries
per phase. Following acquisition of criterion with a 5min delay
between phases the delay was then increased to 30min, then 1 h,
then 3 h, and finally 6 h. A total of 80 trials were completed for
this task across all delay periods. A 6 h delay period has previously
been shown to significantly increase error rates (Phillips et al.,
2004) therefore providing a suitable platform to investigate any
MPH induced improvements in DSWT performance. This delay
(6 h) also far exceeds the time taken for oral MPH to washout in
rats (approximately 2 h) (Patrick et al., 1984) and for any changes
in transmitter levels induced by the drug to return to baseline lev-
els (Kuczenski and Segal, 2002; Berridge et al., 2006). Therefore,
any effects ofMPH administered in the training phase would have
returned to baseline levels before the test phase. Thus, drug effects
relevant to each stage could therefore be neatly dissociated. Prior
to beginning the task with a 6 h delay rats were randomly allo-
cated into four groups: those that received a vehicle in both phases
(N = 5); those that received MPH in both phases (N = 5); those
that received vehicle in the training phase and MPH in the test
phase (N = 4); and those that received MPH in the training phase
and vehicle in the test phase (N = 4). Therefore, it is important
to note that rats only received MPH or vehicle once they pro-
gressed to the 6 h delay and not at any of the previous delays.
Unlike the RFNDT, rat numbers allowed all rats to be tested as
a single cohort.
Arm entries and exits were as defined in the RFNDT. Four
dependent variables were measured in both phases of the DSWT:
baited arm entry, baited arm re-entry, latency to reach the first
arm choice, and mean arm choice time (time to complete the
phase/number of choices made). In the test phase a number of
additional measures were collected. Firstly, unbaited arm entries
were recorded. These constitute entries into any of the training
phase arms which are, by design, unbaited in the test phase. Such
errors are referred to as “across phase” errors and has a ceiling
score of four. Secondly, re-entry into unbaited arms was mea-
sured. Finally the total re-entry into any arm previously visited
in the test phase, termed “within phase” errors was measured.
As with the first task all data were deemed suitable for analy-
sis with parametric tests following normality checks using the
Kolmogorov-Smirnov test and where necessary corrections for
violations of homogeneity of variance were applied (Greenhouse-
Geisser). All analyses were therefore conducted using a 1 within
(TRIAL), 1 between (TREATMENT) ANOVA.
DRUG TREATMENT
Animals were trained to receive oral administration of apple juice
for 5 days prior to starting any behavioral training. This method
removes the ethical and welfare concerns of repeated gavage
and closely replicates the method of administration in humans
(Wheeler et al., 2007). In addition, once trained the animals easily
receive the juice even after long periods without administration.
This allows habituation to the administration technique to take
place prior to training on a behavior task. A stock solution of
MPH hydrochloride (Sigma, UK) was made in distilled water
and frozen at −20◦C until use. Immediately prior to use it was
defrosted and diluted into apple juice to give either 3.0mg/kg or
5.0mg/kg dose. The vehicle solution consisted of the same volume
of distilled water, also previously frozen, diluted into apple juice
immediately prior to use. Previous research has shown that MPH
has therapeutic efficacy in treating individuals with ADHD when
blood plasma levels are in the range of 8–40 ng/ml (Swanson and
Volkow, 2001). Given one of the main sources for MPH as a
cognitive enhancer is likely to be the ADHD prescribed medica-
tion it is appropriate to use similar doses in the present study.
It has also been demonstrated that this level can be achieved
in rats using the same method of oral administration in apple
juice employed here with doses between 1mg/kg (9.56 ng/ml)
and 5mg/kg (36.61 ng/ml) (Wheeler et al., 2007). These levels
were reached 15min after administration, allowing time for the
blood plasma levels to peak (Patrick et al., 1984), and around
5min before effects on neurotransmitter levels have been shown
to peak after oral administration (Kuczenski and Segal, 2002;
Berridge et al., 2006). Although doses as low as 1mg/kg have been
shown to be therapeutically relevant when administered orally
there is some inconsistency in the effects on dopamine and nora-
drenalin levels at the lower levels of the therapeutic range. For
example, previous research using oral administration, albeit by
gavage, has found a dose of 2mg/kg increases dopamine levels
in the PFC and NAc (Berridge et al., 2006), whilst others found
that 2.5mg/kg does not increase dopamine levels in the NAc (PFC
not tested) but 5.0mg/kg does (Kuczenski and Segal, 2002). For
noradrenalin, previous research has revealed increases in hip-
pocampal noradrenalin with orally administered doses as low as
1.0mg/kg (Kuczenski and Segal, 2002), whilst intraperitoneally
administered MPH was shown to increase noradrenalin in the
PFC (Berridge et al., 2006) at doses corresponding to mid and
high therapeutic doses. Due to the inconsistent previous findings
for lower doses of MPH we opted for a “low dose” of 3.0mg/kg
which would, with this route of administration, represent mid
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therapeutic levels and a “high dose” of 5.0mg/kg, corresponding
to the higher end of the range. Administration was 20min prior
to placement on the maze or in activity monitoring chambers
based on previous research demonstrating that this period was
sufficient for orally administered drug to have significant effects
on noradrenalin and dopamine levels (Kuczenski and Segal, 2002;
Berridge et al., 2006). All behavioral testing was conducted blind
to the substance administered.
RESULTS
LOW AND HIGH DOSES OF MPH HAD SIGNIFICANTLY DIFFERENT
EFFECTS ON THE TIME TAKEN TO REACH CRITERION PERFORMANCE
ON THE RFNDT BUT DID NOT AFFECT LOCOMOTOR ACTIVITY
All rats reached criterion performance (an average of 1 or less
re-entry errors on two consecutive days) within 20 days of test-
ing, indicating they had attained a level of expertise on the
task. One Way ANOVA revealed there was a significant differ-
ence in the number of days taken to reach criterion perfor-
mance between the three treatment conditions [F(2, 35) = 4.78;
p = 0.015]. Figure 2A shows that the fastest group to reach cri-
terion were those treated with 3.0mg/kg MPH (mean ± SEM,
6.44 ± 0.69 days), whilst the slowest were those treated with
5.0mg/kgMPH (11.78± 1.73 days). Post-hoc Tukey tests revealed
that the rats treated with 3.0mg/kg MPH were not significantly
different from those treated with the vehicle (p < 0.582) but were
significantly quicker to reach criterion performance than those
treated with 5.0mg/kg MPH (p = 0.015). The group treated with
5.0mg/kg showed a trend toward being significantly slower than
those treated with the vehicle (p = 0.053) who took 8± 0.87 days
to reach criterion.
All remaining data were analyzed with a 1 within (TRIAL),
1 between (TREATMENT) ANOVA (Table 1; Figures 2B–H).
There were significant main effects of TRIAL for all dependent
variables. These main effects were as expected as performance
improves with number of trials. There were no significant main
effects of TREATMENT on any of the measures taken. In the
majority of cases there was no significant TREATMENT× TRIAL
interactions. However, significant interactions were found for
latency and unbaited arm entry. For latency, post-hoc ANOVA
and Tukey tests revealed significant differences between the three
treatment groups on trials 2, 3, 9, and 10. For trial 2, those
treated with 3.0mg/kg MPH had a significantly higher latency
than those in the 5.0mg/kg group. However, in the remaining
trials where significant differences were found the group given
5.0mg/kg MPH had a significantly higher latency than the vehi-
cle treated group (Trials 3, 9, and 10) and the 3.0mg/kg treated
group (Trial 9). It is likely the differences seen in these trials
resulted in the interaction effects seen. This is further supported
with a 1 within 1 between ANOVA excluding these trials result-
ing in a non-significant interaction effect. For unbaited re-entry,
the same post-hoc tests reveal significant differences between the
two drug treatment conditions on trials 2 and 16 and a signifi-
cant difference between the 3.0mg/kg treatment group and the
vehicle group on trial 19. In all three cases the 3.0mg/kg MPH
group had greater re-entry errors. It is likely these trials resulted
in the interaction effects seen. This is further supported with a
1 within 1 between ANOVA excluding these trials resulting in a
non-significant interaction effect. Despite these significant inter-
actions, the greatest differences seen in estimated marginal means
equated to less than 2 arm re-entries and 25 s on the maze, indi-
cating these interactions are likely to be a result of individual
differences in performance.
Previous research (Zhu et al., 2007) found effects of a simi-
lar dose of orally administered MPH when only the early trials
were examined. As such we repeated the ANOVAs outlined above
restricting the trials to 1–5. We found no significant main effects
of TREATMENT for any of the measures indicating that even
in the first 5 days when the most learning occurs, MPH had no
effect on the different measures of maze activity. These restricted
ANOVAs showed similar significant main effects of TRIAL as
the full ANOVA for latency, mean arm choice time, baited entry,
unbaited re-entry, and total-re-entry. However, there was no sig-
nificant main effect of TRIAL on baited re-entry and unbaited
entry when this restricted period was considered. There were no
significant interactions with this restricted period for all measures
except latency which showed a significant interaction, as in the
main ANOVA. Post-hoc tests reveal that this is likely to be due to
the significant group differences on trials 2 and 3 that have been
previously described above.
Activity monitoring of the three groups revealed significant
effects of BLOCK for each measure (Table 2; Figures 3A–D). This
is expected for locomotor activity as the rats reduce spontaneous
behaviour with duration in the chamber. There were no signifi-
cant main effects of TREATMENT or BLOCK × TREATMENT
interactions for any of the measures. Given the rats spent only
around 5min on the radial maze during the RFNDT, we com-
pared also the activity levels in the first 5min block for all mea-
sures across treatment conditions. There were no significant dif-
ferences for any of the measures: ambulatory activity [F(2, 35) =
0.44; p > 0.05]; ambulatory distance [F(2, 35) = 0.86; p > 0.05];
average velocity [F(2, 35) = 0.29; p > 0.05]; and stereotypic activ-
ity [F(2, 35) = 0.05; p > 0.05].
LOW DOSE METHYLPHENIDATE MAY RESULT IN A STATE-DEPENDENT
EFFECT ON DWST
Given the high dose had shown a trend toward impairing perfor-
mance in the RFNDT and we were most interested in enhance-
ment of performance in this study, we only used the lower dose
for the DSWT. In order to be certain that any effects on perfor-
mance at the 6 h delay were due to the administration of MPH
rather than differences in group performance prior to this delay
and drug administration, we examined performance on the train-
ing and test phases of the 3 h DSWT according to the treatment
grouping used for the 6 h DSWT. All data were analyzed with a
1 within (TRIAL), 1 between (FUTURE TREATMENT) ANOVA
for both the training and the test phases on this task. For the train-
ing phase all animals entered all four baited arms on every trial
and therefore performance was identical across groups and tri-
als for baited arm entry. For the remaining dependent variables,
there was no main effect of TRIAL (Table 3, Figures 4A–C) or
FUTURE TREATMENT on any measure. Finally, there were no
TRIAL × TREATMENT interaction effects for baited re-entry or
mean arm choice time. However, there was a significant interac-
tion for latency. Post-hoc ANOVA and tukey tests revealed that
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FIGURE 2 | (A) Rats treated with 5.0mg/kg MPH took significantly longer to
reach criterion on the RFNDT than those treated with 3.0mg/kg although
neither differed significantly from the vehicle-treated group. However, there
were no significant main effects of treatment for any other measure of radial
maze performance, ∗p < 0.05: (B) latency to first arm choice (C) mean arm
choice time (D) baited arm entry (E) baited arm re-entry (F) unbaited arm
entry (G) unbaited arm re-entry and (H) total re-entries made. All graphs
show mean ± SEM.
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Table 1 | Results of 1 within (TRIAL), 1 between (TREATMENT) ANOVA on the RFNDT.
Measure Main effect of treatment Main effect of trial Interaction effect
Latency to first arm choice F(2, 33) = 0.09 F(4.89, 161.29) = 16.94** F(9.78, 161.29) = 2.40*
Mean arm choice time F(2, 33) = 0.02 F(2.09, 69.10) = 13.39** F(4.19, 69.10) = 1.74
Baited entry F(2, 33) = 2.32 F(2.29, 75.51) = 17.49** F(4.58, 75.51) = 1.57
Baited re-entry F(2, 32) = 1.26 F(8.06, 257.91) = 5.14** F(16.12, 257.91) = 0.67
Unbaited entry F(2, 33) = 1.14 F(9.34, 308.33) = 2.97* F(18.67, 308.33) = 1.73*
Unbaited re-entry F(2, 33) = 0.50 F(6.43, 212.15) = 13.86** F(12.86, 212.15) = 1.02
Total re-entry F(2, 32) = 1.02 F(7.73, 247.46) = 10.72** F(15.47, 247.48) = 0.90
There were no significant main effects of TREATMENT. There were significant effects of TRIAL as the animals’ performance improved with increased trials. There
were two significant interaction effects for latency and unbaited arm entry. *p < 0.05, **p < 0.001.
Table 2 | Results of 1 within (BLOCK), 1 between (TREATMENT) ANOVA on the locomotor activity.
Measure Main effect of treatment Main effect of block Interaction effect
Ambulatory counts F(2, 33) = 0.79 F(4.41, 145.51) = 101.69** F(8.82, 145.51) = 0.94
Ambulatory distance F(2, 33) = 1.51 F(7.25, 239.30) = 152.03** F(14.50, 239.30) = 1.26
Average velocity F(2, 33) = 0.48 F(6.97, 230.14) = 3.17* F(3.95, 230.14) = 0.95
Stereotypic activity F(2, 33) = 0.56 F(4.87, 160.76) = 85.89** F(9.74, 160.76) = 0.99
There were no significant main effects of TREATMENT. There were significant effects of BLOCK as the animals’ activity decreased with duration in the chamber.
There were no significant interaction effects. *p < 0.05, **p < 0.001.
there was a significant difference between the MPH/MPH and
MPH/VEH group on trial 7 and trial 11 with the latter having
a significantly longer latency in both cases (p < 0.05). It is likely
that these differences resulted in the significant interaction effect,
a suggestion supported by the lack of interaction seen when these
trials were removed from the main analysis.
For the 3 h DSWT test phase there were main effects of
TRIAL on latency and mean arm choice time (Table 3, Figure 5)
and main effects of FUTURE TREATMENT on baited re-entry,
unbaited re-entry, within phase errors, and total arm visits.
For baited re-entry post-hoc Tukey tests show that prior to any
drug administration, the animals allocated to the MPH/Veh
group had significantly more re-entry errors than the Veh/MPH
group (p = 0.019) and the Veh/Veh group (p = 0.011). Similarly,
for unbaited re-entry, the animals allocated to the MPH/Veh
group had significantly more unbaited re-entries than those in
all other groups (MPH/MPH p = 0.024; Veh/MPH p = 0.033;
Veh/Veh p = 0.024). For within phase errors post-hoc Tukey
tests indicated that prior to any treatment the animals allo-
cated to the MPH/Veh group made significantly more within
phase errors than the Veh/Veh group (p = 0.002); MPH/MPH
group (p = 0.014) and the Veh/MPH group (p = 0.006). Finally
for the total arm visits, animals allocated to the MPH/Veh
group showed significantly more arm entries than those allo-
cated to the Veh/Veh groups (p = 0.011). These data indicate
that prior to any drug treatment the rats subsequently allocated
to the MPH/Veh group made more errors in the test phase.
There were no significant TRIAL × FUTURE TREATMENT
interactions.
Given the presence of significant main effects and inter-
actions prior to actual drug treatment in the 6 h delay, we
conducted an Analysis of Covariance for the 6 h DSWT with
the individual mean score for each measure at the appropri-
ate phase for the 3 h delay as a fixed covariate. A fully factorial
ANCOVA includes all interaction terms between the covariate,
within- and between-factors. Main effects of the within fac-
tor (TRIAL) are independent of the performance at the 3 h
delay and therefore, pure repeated-measures effects are reported
from an analysis that excludes the covariate, and so degrees of
freedom differ for pure within effects and between effects or
interactions.
During the training phase there was no significant main effect
of TRIAL or TREATMENT on any of the dependent variables
(Table 4). Similarly there were no significant interaction effects
between these variables. During the test phase there were no main
effects of TRIAL on any dependent variable. For the majority of
variables there was no significant main effect of TREATMENT.
However, there was a significant effect of TREATMENT on baited
re-entry errors (Figure 6). Contrast analysis revealed that there
were no significant differences between the group given the vehi-
cle in both phases and the group given MPH in both phases or
just given MPH in training phase. However, if MPH was given in
just the test phase, there were significantly more re-entry errors
into baited arms relative to the group given solely the vehicle
(p = 0.01) or solely MPH (p = 0.01) (Figure 6). There was also a
trend toward a significant main effect of TREATMENT for across
phase errors. Contrast analysis showed that this was likely due to
the number of across phase errors made when MPH was present
in both phases or just the test phase being higher than when it was
present in only the training phase (p < 0.05).
There were no significant TRIAL × TREATMENT interac-
tions for latency; mean arm choice time; baited entry; across
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FIGURE 3 | There were no effects of MPH on measures of locomotor
activity (A) ambulatory activity (B) ambulatory distance (C) average
velocity (D) stereotypic activity for the animals that completed the
RFNDT. Note that stereotypic activity would also have captured normal
grooming behavior which may explain the initially high levels. All graphs show
mean ± SEM.
Table 3 | Results of 1 within (TRIAL), 1 between (FUTURE TREATMENT) ANOVA on the DSWT using a 3 h delay demonstrate that there were
some differences between the four treatment groups used for the 6h delay prior to any administration.
Main effect of future treatment Main effect of trial Interaction effect
TRAINING PHASE MEASURE
Latency to first arm choice F(3, 14) = 1.25 F(4.52, 63.31) = 1.81 F(13.57, 63.31) = 1.96*
Mean arm choice time F(3, 14) = 0.47 F(2.80, 39.15) = 1.30 F(8.39, 39.15) = 0.72
Baited re-entry F(3, 14) = 0.49 F(2.88, 39.51) = 1.39 F(8.47, 39.51) = 1.32
TESTING PHASE MEASURE
Latency to first arm choice F(3, 14) = 1.75 F(4.46, 62.44) = 3.70* F(13.38, 62.44) = 1.82
Mean arm choice time F(3, 14) = 2.45 F(4.98, 69.76) = 4.03** F(14.95, 69.76) = 1.14
Baited entry F(3, 14) = 1.21 F(1, 14) = 1.296 F(3, 14) = 1.21
Baited re-entry F(3, 14) = 5.56* F(1.94, 27.18) = 1.86 F(5.82, 27.18) = 1.07
Unbaited re-entry F(3, 14) = 5.08* F(1.45, 20.28) = 1.62 F(4.35, 20.28) = 1.52
Across phase errors F(3, 14) = 0.56 F(11, 154) = 1.52 F(33, 154) = 0.82
Within phase errors F(3, 14) = 8.30* F(2.05, 28.63) = 2.38 F(6.14, 28.63) = 1.03
Total arm visits F(3, 14) = 4.94* F(4.38, 61.29) = 1.79 F(13.13, 61.29) = 0.69
*p < 0.05, **p < 0.001.
phase errors or unbaited re-entry. There were significant inter-
actions for baited re-entry; within phase errors and total arm
visits (Figure 7). In all cases of significant interactions post-
hoc ANOVA and tukey analysis revealed a significant difference
between the groups on Trial 9. For the baited re-entries and
within phase errors the Veh/MPH group differed significantly
from all other groups with a higher number of errors. For the
total arm visits the same group differed significantly from the
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FIGURE 4 | Performance during the training phase on the 3h DWST over
the 12 trials run at this delay demonstrate that there were pre-existing
group differences for the different drug treatment conditions used at
the subsequent 6 h delay for (A) latency (B) mean arm choice time (C)
re-entry in to baited arms. All graphs show mean ± SEM.
MPH/MPH group and the MPH/Veh group. In all cases if this
trial was removed from analysis there was no longer a signif-
icant interaction. There was no specific outlier which could
account for these differences and, although significant, the differ-
ences are small and therefore may have arisen through individual
differences.
DISCUSSION
EFFECTS ON NON-DELAYED LEARNING
In the non-delay task behavioral variability (as assessed by stan-
dard deviations) decreased across days as would be expected
during task learning. This rate of change in variability was the
same in both groups at the low dose. At the high dose the
vehicle group showed lower variability at the start of testing
but both groups reached similar levels within the first three
trials and continued at these levels until the end of testing.
As is usual with behavioral testing there was a degree of inter
and intra-individual variability in performance and this was
higher for the time measures (e.g. latency to first arm, mean
arm choice time). It is important to note that order effects
were controlled for because the order of testing was reversed
on alternate testing days and drug administration was evenly
distributed across the order of testing. Unfortunately objec-
tive statistical analysis of order effects is not possible due to
the limited number of animals in each group. Animals were
randomly assigned to groups to attempt to control for individ-
ual differences but a number of effects arose throughout the
results suggesting that management of potential individual dif-
ferences would have been better achieved using larger group
sizes to add power. Unfortunately there are physical constraints
on the number of animals that can be feasibly tested in a sin-
gle day. Thus, it is possible that any lack of effect of MPH
reflects the power of our study although we note that our study
was able to detect some significant effects of MPH which we
discuss below.
Our data revealed that neither dose of MPH had a signifi-
cant effect on performance of the non-delayed random forag-
ing task compared to the control group, although there was a
trend toward a delay in reaching criterion for the higher dose
(5.0mg/kg). This result was unexpected because this task has
been shown to rely on transmission between the NAc and hip-
pocampus (Kesner and Dimattia, 1987; Floresco et al., 1997).
These two structures would be affected by MPH which acts to
increase levels of dopamine and noradrenalin in these struc-
tures, respectively. Although we did not directly measure brain
activity underlying performance we suggest that it is likely to be
changes in NAc dopamine that would affect performance. This
is because previous studies have shown that random foraging
behaviour, as assessed in the current study in the non-delay task,
can be dose-dependently impaired by administration of haloperi-
dol into the NAc shell (Floresco et al., 1996). Furthermore,
whilst noradrenalin is known to be a powerful modulator of hip-
pocampal activity (Moore and Bloom, 1979; Loy et al., 1980;
Mueller et al., 1982; Madison and Nicoll, 1988; Gereau and Conn,
1994), behavioral studies using radial maze tasks have found
noradrenalin manipulations ineffective at altering performance
(Myhrer, 2003).
Assuming that it is NAc dopamine that is critical to this task,
it is possible that it was the level of training experienced that
resulted in our lack of effect of MPH on task performance. The
work by Floresco et al. (1996) involved administering a dopamin-
ergic drug to rats which were highly trained and had already
reached criterion on the task. However, in the present study, we
administered MPH throughout training and therefore it is possi-
ble that the effect of increased dopamine is not as evident, if at all,
in animals still learning the task. Certainly, learning-dependent
effects of NAc dopamine levels have been previously suggested
to underlie differences in dopamine effects on other radial maze
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FIGURE 5 | Performance during the test phase on the 3h DWST over the
12 trials run at this delay revealed that there were some pre-existing
group differences for the treatment groups selected for the 6h delay.
(A) latency (B) mean arm choice time (C) baited arm entry (D) across phase
errors data did not show pre-existing differences. By contrast (E) baited arm
re-entry (F) unbaited arm re-entry (G) within phase errors and (H) total
number of arm visits data did show pre-existing differences. Prior to any drug
treatment animals allocated to the MPH/Veh group made more within phase
errors and re-entries into unbaited arms than the other three groups. These
animals also showed greater baited re-entry in comparison to the Veh/MPH
and the Veh/Veh group and more arm visits overall than the Veh/Veh group.
These data demonstrate that prior to any drug treatment the rats
subsequently allocated to the MPH/Veh group made more errors in the test
phase. All graphs show mean ± SEM.
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Table 4 | Results of 1 within (TRIAL), 1 between (TREATMENT) ANCOVA for the 6 h DSWT, with performance at the 3h delay as a fixed
covariate.
Main effect of treatment Main effect of trial Interaction effect
TRAINING PHASE MEASURE
Latency to first arm choice F(1, 15) = 0.32 F(1.45, 23.18) = 0.64 F(1.47, 29.17) = 0.91
Mean arm choice time F(1, 15) = 0.03 F(3.54, 56.67) = 1.03 F(4.04, 60.61) = 1.30
Baited entry F(1, 15) = 0 F(1.98, 31.61) = 0.89 F(1.98, 31.61) = 1.11
Baited re-entry F(1, 15) = 1.38 F(3.70, 59.17) = 1.17 F(3.67, 54.99) = 0.84
TESTING PHASE MEASURE
Latency to first arm choice F(3, 12) = 0.53 F(2.42, 31.39) = 2.30 F(7.16, 28.65) = 1.21
Mean arm choice time F(3, 12) = 0.81 F(4.49, 58.34) = 1.268 F(12.50, 49.99) = 0.95
Baited entry F(3, 13) = 0 F(1, 14) = 1.30 F(1, 14) = 0
Baited re-entry F(3, 13) = 4.66* F(3.55, 49.77) = 3.50 F(9.74, 42.22) = 3.70**
Unbaited re-entry F(3, 13) = 1.84 F(2.78, 38.85) = 2.24 F(8.39, 36.36) = 1.29
Across phase errors F(3, 13) = 3.05α F(4.68, 65.54) = 1.15 F(13.96, 60.51) = 0.80
Within phase errors F(3, 13) = 2.60 F(4.31, 60.34) = 2.15 F(12.04, 52.19) = 2.06*
Total arm visits F(3, 13) = 0.86 F(4.67, 65.44) = 1.31 F(12.94, 50.07) = 2.31**
*p < 0.05, **p = 0.001 α identified as a trend toward significance with a p = 0.067.
FIGURE 6 | With performance on the 3h DSWT as a fixed covariate, an
ANCOVA showed there are no significant differences in the number of
baited re-entries between groups given methylphenidate (MPH) or
vehicle (Veh) in both phases on the 6h delay. However, giving
methylphenidate in just one phase increases the number of errors. When
methylphenidate is given only in the test phase, this increase is significantly
different from groups given the same treatment in both phases. All graphs
show mean ± SEM. ∗∗p = 0.01.
tasks (Kim and Levin, 1996). A related explanation for the incon-
sistency may be that the increase in motivation derived from
higher accumbens dopamine levels effectively increased distrac-
tion (Kim and Levin, 1996) and that, during learning, rather
than once trained, this could counter any dopamine-related
improvement.
Nonetheless, the training level would not explain why we did
not find effects whilst a previous study using orally administered
MPH throughout learning did show some effects on a similar task
(Zhu et al., 2007). Zhu et al. (2007) examined the effects of orally
administered 3.0mg/kg MPH on non-delay performance when
all eight arms of the maze were baited. The results from this study
partially concur with our own in that there was no effect on the
time taken to reach criterion on the task or locomotor measures.
They also found similar main effects of trial on a number of mea-
sures, as to be expected with a learning task. However, in contrast
to the current results they found some main effects of treatment,
which showed improvements in performance with the drug, espe-
cially when narrowing to the early phases of learning. There may
be a number of reasons for the discrepancy in findings between
this study and our own. Firstly, the task employed by Zhu et al.
(2007) had all eights arms baited, in contrast to the four baited
on our task, making the Zhu et al. (2007) task easier. However,
this seems unlikely to explain the difference because the training
phase of the DSWT, which is very similar to the task employed by
Zhu et al. (2007), also showed no significant effects of treatment.
Secondly, although oral administration was employed by Zhu
et al. (2007) they used administration via food. This could have
altered bioavailability in comparison to our study. It is possible
that the changed bioavailability reduced the size and/or dura-
tion of the effect of MPH on the relevant neurotransmitters and
brain structures. We suggest that this is unlikely because we were
using doses and time scales previously validated by blood plasma
measures. However, as we did not measure blood or brain levels
of the drug in the current study we cannot rule out the lack of
effects being due to ineffective doses. Thirdly, Zhu et al. (2007)
used younger rats (PND 22-39) with the main effects seen dur-
ing early phases of testing (PND 22-28), in contrast to our own
rats which were PND 60 at the start of testing. We deliberately
selected this adult age to mirror the use of cognitive enhancers in
adults (Sahakian and Morein-Zamir, 2007) but it is possible that
this may have contributed to the differences in findings between
the two studies. Certainly, there is evidence that the PFC and,
in particular, dopamine innervation of it, does not reach matu-
rity until at least P60 (Kalsbeek et al., 1988), which may affect
the neural substrates of the task. It may also mean that perfor-
mance is generally poorer in younger animals. Indeed, Zhu et al.
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FIGURE 7 | At the 6h delay DSWT there were significant interaction
effects between trial and treatment on (A) baited re-entry (B) total arm
visits (C) within phase errors. Although interpretation of the interactions
displayed in (A) and (C) is difficult due to the small numbers involved,
restricted ANOVA suggested that the interaction they are all due to
increased scores recorded for the Veh/MPH group on trial 9. All graphs
show mean ± SEM.
(2007) suggested that they found effects only at this young age
because rats of this age normally perform poorly on the radial
maze tasks (Chambers et al., 1996), and show reduced exploratory
behaviour (Galef, 1981), effectively creating additional scope for
drug effects. Finally, Zhu et al. (2007) conducted their research
using both male and female Sprague Dawley rats whilst we used
only male Hooded Lister rats in the present study. Although Zhu
et al. (2007) report that there were no effects of sex on any of
the results, indicating that this is unlikely to account for the
differences between the two studies; differences in strain have
been shown to affect radial maze performance. For example, it
has been demonstrated that Hooded Lister rats performed bet-
ter than Wistar rats on a radial maze task in the first five trials
(Manahan-Vaughan and Schwegler, 2011). In addition, previous
work demonstrates that, again in the first five trials on a simi-
lar radial maze task, Wistar rats performed better than Sprague
Dawley rats (Higashida and Ogawa, 1987). Therefore, the differ-
ences seen between the two studies may relate to differing baseline
levels of performance in the two strains selected. Based on this
previous research, we speculate that Hooded Lister rats may per-
form better at baseline than other strains and, given the reported
baseline-dependency of MPH (Clatworthy et al., 2009) with only
poor performers benefitting, this could explain the lack of effect
in the current study of a dose previously found to be effective.
Although there was no significant effect of the 5.0mg/kg MPH
relative to the control group beyond a trend toward increas-
ing the time taken to reach criterion, the 5.0mg/kg group did
perform significantly worse than those given 3.0mg/kg MPH in
terms of reaching criterion. Examination of the different mea-
sures did not reveal any main effects of treatment over the entire
duration or when the analysis was limited to the first five tri-
als. One possible explanation for this is that rats treated with
5.0mg/kg take longer to reach criterion because they are dis-
playing stereotypic behaviour, confounding performance on the
RFNDT. However, this seems unlikely because other radial maze
measures were unaffected and locomotor monitoring did not
reveal any significant stereotypy in any group. However, it should
be acknowledged that the automated recording of stereotypy may
be less optimal than direct behavioral observation because the
software detects any partial body movement within a defined
space. Whilst this will detect stereotypic movements such as
head weaving and grooming chains (Taylor et al., 2010), it may
also include normal grooming behaviors, which could mask real
stereotypic activity. In any event, previous research investigat-
ing stereotypy typically uses higher doses of psychostimulants
administered intraperitoneally (Walker et al., 2010).
An alternative explanation is that this detrimental effect on
task performance at a higher dose is a result of the complex rela-
tionship between cognitive function and dopamine levels thought
to best describe an inverted U-shaped relationship between the
two (Roberts et al., 1994; Williams and Goldman-Rakic, 1995;
Mattay et al., 2003; Cools and D’Esposito, 2011). Irrespective of
the exact neurotransmitter mechanisms, dose-dependent effects
of MPH have also been previously reported on other cognitive
tasks in both clinical human populations (Sprague and Sleator,
1977; Tannock et al., 1995), and healthy animals (Berridge et al.,
2006; Arnsten, 2009; Gamo et al., 2010). However, the prior work
in healthy animals, and therefore the most comparable to the
present study, has focussed on working memory tasks dependent
on the PFC (Berridge et al., 2006; Arnsten, 2009; Gamo et al.,
2010). Whilst it is probable that, with the doses employed, there
would have been some increase in dopamine and noradrenalin
in this region (Berridge et al., 2006) in the present study, we do
not think the effects seen were mediated by changes in the PFC
because this area is not a critical structure in performance of
the RFNDT. Further research would be required to investigate
this fully, but to our knowledge this is the first study showing a
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dose-dependent effect of MPH on a task that is dependent on the
hippocampal-NAc circuitry.
EFFECTS ON DELAYED LEARNING
As for the RFNDT animals were randomly assigned to groups to
attempt to control for individual differences but again a num-
ber of effects arose throughout the results suggesting that power
and therefore sensitivity could have been improved with larger
group sizes. Most notably the random allocation to groups unfor-
tunately generated a significant difference in error performance
in the MPH/VEH group in the DSWT which we controlled sta-
tistically using ANCOVA. However, it is possible that this group
effect at 3 h contributed to the lack of significance of the state
dependent effect in this group compared to the VEH/MPH group
at 6 h (discussed below). In the DSWT we found no effect of
MPH in the training phase, which is perhaps unsurprising given
its similarity to the RFNDT, albeit even simpler, with only four
arms open and all being baited. However, when examining the
test phase of the DSWT we did see effects of drug treatment
on the number of re-entries into baited arms. The group given
MPH during training and test phases did not differ signifi-
cantly from those given the vehicle in both phases. However,
when the drug was only present in one phase there appeared
to be an increase in the number of errors relative to both these
groups (MPH/MPH and Veh/Veh), although this only reached
significance for the Veh/MPH group. Therefore, when the same
treatment state, be it MPH or vehicle, was present in both the
training and test phase there was no overall difference in perfor-
mance between drug treated animals and controls. In contrast
when the treatment state in the phases differed, performance
may be impaired in drug treated animals. This represents a state-
dependent effect similar to state-dependent learning. A number
of studies have previously reported state-dependent learning with
MPH in humans (Swanson and Kinsbourne, 1976; Shea, 1982;
Pozzi and Hartley, 1984) but they have all focused on a clin-
ical population with ADHD or hyperactivity. Moreover, even
within this population results are conflicting with Becker-Mattes
et al. (1985) failing to find the effect. Therefore, to our knowl-
edge, this is the first report indicative of a state-dependent effect
in healthy individuals given MPH. Although a state dependent
learning effect would be likely to manifest in the across phase
errors this measure has reduced sensitivity as it has a ceiling
score of four. In addition it is interesting that the state depen-
dent effect occurs in the re-entries to baited arms in the test
phase which suggests that animals have difficulty matching loca-
tion to reward when the contextual state is different between
phases.
Although the state dependent effect observed may relate to
changes in arousal level, such as through noradrenergic changes,
or motivation, this seems unlikely in the current study because
there were no group effects on the number of pellets consumed,
with all rats consuming the maximum. Moreover there were no
differences in the latency of arm choices, which may be expected
to differ if motivation or arousal were affected. Therefore, it is
possible that the state dependent effect we observed is due to spe-
cific actions of the drug on neurotransmitter levels. Previous work
has shown that dopamine in the PFC is important in performance
on the DSWT (Floresco and Phillips, 2001). Microdialysis has
shown that there is an increase in dopamine efflux during the
DSWT training phase which is associated with searching and
eating the reward pellets (Phillips et al., 2004). This increase
then returns to baseline levels after approximately 5min and
it is thought that the hippocampus is responsible for main-
taining the memory for food reward location during the delay.
However, during the test phase, Phillips et al. (2004) report an
almost identical increase in dopamine efflux that is present even
when the food reward is unavailable. When the delay is unpre-
dictably increased (to 1 or 6 h) the level of dopamine efflux
decreases and the number of errors made increases during the
test phase. In the current study we would expect the normal
efflux of dopamine to have occurred during the training phase.
However, although we increased the delay to 6 h this was from
only 3 h, unlike Phillips et al. (2004) who increased it from 30min
to 6 h. As such, we suggest that some dopamine efflux would
still have occurred at the 6 h delay, comparable to that found
by Phillips et al. (2004) for their 1 h delay as the magnitude of
increase (i.e., multiplied by two) was the same. However, since
we did not measure dopamine levels directly this remains an
assumption.
In sum our results could have implications for individuals
attempting to achieve cognitive enhancement with MPH. From
the current study it seems that at best performance may remain
unchanged at the doses employed and at worst performance could
be impaired. When delays are involved and MPH is taken in
both phases, there is no improvement in performance compared
to not having MPH at all and, at worse, when only taken in
one phase, it may actually be detrimental. A similar situation
in humans could amount to taking MPH during revision and
during an exam (with this having no effect on performance),
whilst only taking the drug at one stage (revision, or exam only)
might actually decrease performance. Our findings, in rats on
the radial maze at least, suggest that MPH in healthy rats is
not an effective cognitive enhancer, although there are admit-
tedly some important differences between animals working for
an immediate food reward on a maze and students working
toward the delayed goal of passing an exam. Although we have
noted some limitations to our study in terms of power and sen-
sitivity our findings are supported by a recent review (Lynch
et al., 2011). Of course, the functions assessed in the present
study were limited to specific measures relating to goal-directed
learning and memory and therefore one could argue that there
are many other functions which could be enhanced. However,
it should be noted that these functions were deliberately cho-
sen because of their likely sensitivity to the neurochemical effects
of MPH and therefore the negative findings of this study are of
interest.
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